What's in TaiMed Biologics Inc.'s pipeline?

TaiMed Biologics Inc. has 3 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with TaiMed Biologics Inc.'s portfolio?

Top competitors by shared drug class: Breath of Life International Pharma Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/taimed-biologics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

TaiMed Biologics Inc. — Portfolio Competitive Intelligence Brief

TaiMed Biologics Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
ibalizumab-uiyk	ibalizumab-uiyk	phase 3	CD4 receptor antagonist	CD4	Infectious Disease

Therapeutic area mix

Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Breath of Life International Pharma Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for TaiMed Biologics Inc.:

Cite this brief

Drug Landscape (2026). TaiMed Biologics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/taimed-biologics-inc. Accessed 2026-05-16.